Dr. Brenda Schulman is Director of the Department of Molecular Machines and Signaling at Max Planck Institute of Biochemistry, Honorary Professor at Technical University of Munich and adjunct faculty at St. Jude Children’s Research Hospital. Dr. Schulman’s research group studies biochemical mechanisms underlying regulation by ubiquitin and autophagy pathways. Her lab has developed methods and tools to probe fleeting intermediates in ubiquitin and ubiquitin-like protein transfer cascades, and implemented them to determine the structural mechanisms of major families of E3 ligases, with a particular focus on dynamic multiprotein complexes including cullin-RING E3 ligases. Dr. Schulman is an elected member of American Academy of Arts and Sciences, the National Academy of Sciences, European Molecular Biology Organization (EMBO), and the German National Academy Leopoldina and has been recognized by awards including most recently the Gottfried Wilhelm Leibniz Prize and Ernst Jung Prize for Medicine. Dr. Schulman received her Ph.D. from Massachusetts Institute of Technology (MIT) studying protein folding with Peter Kim before developing an interest in the regulation of protein degradation during her postdoctoral studies first at Mass General Hospital (MGH) Cancer Center with Dr. Ed Harlow, and then at Memorial Sloan-Kettering Cancer Center with Nikola Pavletich.